Adage Capital Partners
DSGN icon

Adage Capital Partners’s Design Therapeutics DSGN Stock Holding History

Adage Capital Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300,000
Closed -$4.2M – 1065
2022
Q2 		$4.2M Buy
300,000
+100,000
+50% +$1.35M 0.01% 818
2022
Q1 		$3.23M Buy
200,000
+35,000
+21% +$536K 0.01% 869
2021
Q4 		$3.53M Hold
165,000
– – 0.01% 841
2021
Q3 		$2.42M Buy
165,000
+119,888
+266% +$1.99M ﹤0.01% 887
2021
Q2 		$897K Sell
45,112
-154,888
-77% -$3.91M ﹤0.01% 911
2021
Q1 		$5.98M Buy
+200,000
New +$6.75M 0.01% 775

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners's DSGN Position: Q3 2022 in Review

Adage Capital Partners sold out of Design Therapeutics (DSGN) in Q3 2022, closing a stake of 300,000 shares — an estimated $4.2M sold.

Adage Capital Partners first reported a position in DSGN in Q1 2021 and held it in 6 quarters. The position peaked at $5.98M in Q1 2021. 79 funds tracked by Wall St. Rank hold DSGN as of Q3 2022.

  • Adage Capital Partners reported no remaining Design Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Adage Capital Partners sold 300,000 Design Therapeutics shares in Q3 2022, an estimated $4.2M.
  • Adage Capital Partners first reported a position in Design Therapeutics in Q1 2021 and held it in 6 quarters.
  • Adage Capital Partners's Design Therapeutics position peaked at $5.98M in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2022.

Based on Adage Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.